@article {7493,
	title = {Treatment options for relapsed and refractory multiple myeloma},
	journal = {Blood},
	volume = {125},
	year = {2015},
	note = {Cited By :23Export Date: 21 February 2017},
	month = {2015},
	pages = {3085 - 3099},
	abstract = {Over the last few decades, significant improvement in outcomes has been observed for myeloma patients, mainly as a result of the use of currently available approved antimyeloma agents, along with combining autologous stem cell transplantation in the treatment of myeloma. With more targeted agents in development, the treatment of a myeloma patient at relapse has become complicated and, as a consequence, results in vast heterogeneity in treatment patterns. Although a consensus on the timing of initiation of treatment, the choice of agents to be used, and the role of transplant is less clear, we describe an evidence-based approach and the factors to consider upon relapse. We describe additional newer agents and targets that are under development, with the goal of achievement of durable remissions for myeloma patients. {\textcopyright} 2015 by The American Society of Hematology.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929376749\&doi=10.1182\%2fblood-2014-11-568923\&partnerID=40\&md5=ea358b9d46b8f83085c56a195ce21fca},
	author = {Nooka, A.K. and Kastritis, E. and Dimopoulos, M.A. and Lonial, S.}
}
